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Accurate stage determination is crucial in the choice of treatment for patients suffering from sleeping sickness, also
known as human African trypanosomiasis (HAT). Current staging methods, based on the counting of white blood
cells (WBC) and the detection of parasites in the cerebrospinal fluid (CSF) have limited accuracy. We hypothesized
that immune mediators reliable for staging T. b. gambiense HAT could also be used to stratify T. b. rhodesiense
patients, the less common form of HAT.
A population comprising 85 T. b. rhodesiense patients, 14 stage 1 (S1) and 71 stage 2 (S2) enrolled in Malawi and
Uganda, was investigated. The CSF levels of IgM, MMP-9, CXCL13, CXCL10, ICAM-1, VCAM-1, neopterin and B2MG
were measured and their staging performances evaluated using receiver operating characteristic (ROC) analyses.
IgM, MMP-9 and CXCL13 were the most accurate markers for stage determination (partial AUC 88%, 86% and 85%,
respectively). The combination in panels of three molecules comprising CXCL13-CXCL10-MMP-9 or
CXCL13-CXCL10-IgM significantly increased their staging ability to partial AUC 94% (p value < 0.01).
The present study highlighted new potential markers for stage determination of T. b. rhodesiense patients. Further
investigations are needed to better evaluate these molecules, alone or in panels, as alternatives to WBC to make
reliable choice of treatment.
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Human African trypanosomiasis (HAT), commonly
known as sleeping sickness, is a neglected tropical dis-
ease caused by the Trypanosoma brucei parasite and
transmitted to humans through the bite of the tsetse fly
[1]. Two morphologically identical subspecies of para-
sites are responsible for the disease: Trypanosoma brucei
gambiense and T. b. rhodesiense [2]. In both cases, the
disease progresses from a haemolymphatic first stage
(S1), to a meningo-encephalitic second stage (S2). The
latter reflects invasion of the central nervous system
(CNS) by the parasites across the blood–brain barrier
(BBB) with severe neurological complications, which can* Correspondence: Jean-Charles.Sanchez@unige.ch
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in any medium, provided the original work is pultimately lead to coma and death, when untreated [3].
The two forms of HAT differ in their clinical presenta-
tions and geographic distribution. The gambiense form
is widespread in Central and Western Africa and is com-
monly considered to be a chronic infection, which slowly
progresses from the first to the second stage. The rhode-
siense form of sleeping sickness, that affects communi-
ties in Eastern Africa, is a more aggressive illness, which
rapidly progresses to the meningo-encephalitic stage [3]
and accounts for less than 5% of all HAT cases [4]. Con-
trary to T. b. gambiense, for which a relatively safe drug
combination has recently been introduced for treatment
of S2 patients [4-6], treatment of S2 T. b. rhodesiense
patients still relies on melarsoprol [7-9]. Melarsoprol has
been reported to cause reactive encephalopathies in 8%
of T. b. rhodesiense treated patients, which are fatal in
57% of them [8]. As a drug to safely treat both stage 1n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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treatment is associated with severe side effects and tox-
icity [8], stage determination remains a key step in the
management of patients suffering from T. b. rhodesiense
HAT.
Staging is based on the examination of the cerebro-
spinal fluid (CSF) by microscopy. According to WHO,
patients having ≤ 5 white blood cells (WBC) per micro-
liter of CSF and absence of parasites are considered to
be in the first stage of the disease, while patients having
more than 5 WBC/μL and/or presence of parasites in
the CSF are considered as S2 [10]. These methods suffer
from limited specificity and reproducibility of the count-
ing of WBC and lack of sensitivity in finding of parasites
in CSF [11,12] (Dieudonné Mumba Ngoyi, personal
communication).
The discovery of surrogate markers to complement or
replace the counting of WBC in the staging of HAT is
highly desired [11,13,14]. Many studies have focused on
the staging in T. b. gambiense HAT [13,15-20], while less
attention has been paid to T. b. rhodesiense, with a pau-
city of data on staging markers [13,21,22]. Some pro-
and anti-inflammatory factors have been shown to be
associated with the late stage of T. b. rhodesiense sleep-
ing sickness, including IL-10, IL-6, CXCL10 and neop-
terin [13,21,22].
The aim of the present study was to investigate eight
immune-related factors, shown to be powerful markers
for stratification of T. b. gambiense HAT patients [13,15-
20,23], as staging markers for T. b. rhodesiense sleeping
sickness.
Methods
Patients
Eighty five patients (14 stage 1 and 71 stage 2) with evi-
dence of parasites in blood, lymph or CSF were investi-
gated in the present study (Table 1). Patients were
enrolled by active or passive case finding in MalawiTable 1 Pre-treatment characteristics of the investigated
patients
Stage 1 (n=14) Stage 2 (n=71)
Demography
Sex, F (n)* 7 32
Age, years [mean ± SD]† 37.1 [± 19.3] 36.9 [± 15.8]
Geographical origin
Malawi, n 3 27
Uganda, n 11 44
CSF examinations
Trypanosome positive, n 0 64
WBC/μL (median, range) 3 [2–5] 21 [4–1140]
* Fisher’s exact test, no significant differences.
† Mann–Whitney U test, no significant differences.(NEUROTRYP study [13]) and Uganda (FINDTRYP
study), in regions endemic for T. b. rhodesiense HAT.
The studies were approved by the Ministry of Health
and Population, Lilongwe, Malawi and by the Uganda
National Council for Science and Technology (UNCST).
All patients signed a written informed consent before
inclusion into the study. Children (< 18 years old) or
patients with altered mental status were only included in
the studies after written consent of a parent or a guard-
ian. All enrolled patients had the possibility to withdraw
at any moment. Details on sample collection, inclusion
and exclusion criteria of the two cohorts are reported in
Additional file 1: Table 1.
CSF samples were collected by lumbar puncture and the
number of WBC counted. The presence of parasites was
determined using either the modified single centrifugation
(Malawi) [24] or double centrifugation (Uganda) [25]
methods. CSF samples were stored in liquid nitrogen at
the site of collection, followed by storage at −80°C.
Patients were diagnosed, staged and treated for HAT
according to the guidelines of the national sleeping sick-
ness control program of the country of sample collection.
In the present study, patients’ stage was assigned accord-
ing to WHO recommendations [10], i.e., stage 1 when
CSF WBC ≤ 5/μL and absence of parasite in CSF, stage 2
when CSF WBC > 5/μL and/or parasites detected in the
CSF. Patients were excluded when information to classify
them according to these criteria was not available.
Immunoassays
The levels of the markers were measured in pre-
treatment CSF using commercially available immunoas-
says (ELISA or multiplex bead suspension assay) follow-
ing manufacturers’ instructions as reported elsewhere
[23]. These included IgM (ICL, OR, USA), B2MG
(Calbiotech, CA, USA), neopterin (BRAHMS, Germany),
CXCL10 (Bio-Rad, CA, USA), VCAM-1, ICAM-1,
CXCL13 and MMP-9 (R&D Systems, UK).
Statistics
Statistical analyses were performed using IBM SPSS Sta-
tistics version 20.0.0 (IBM, NY, USA). Comparisons be-
tween groups were performed using the Mann–Whitney
U test, setting the level of significance at 0.05. Correla-
tions between molecules and the number of WBC were
assessed through the Spearman correlation rho coeffi-
cient. ROC analyses were performed using pROC pack-
age for S+ version 8.1 (TIBCO, Software Inc.) [26]. All
tests were two-tailed.
To assess the staging ability of each marker and to com-
pare their performances at high specificity, corrected par-
tial areas under the ROC curves (pAUC) were calculated
between 90 and 100% of specificity (SP) [26]. A cut-off
corresponding to 100% specificity was also computed.
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presence of trypanosomes in CSF, patients were classi-
fied based on the absence (n=21) or presence (n=64) of
parasites in their CSF. Complete AUC were then com-
puted as well as the cut-off corresponding to the best
combination of specificity (SP) and sensitivity (SE).
Panels of markers were obtained using an in-house
software, PanelomiX, based on a method of optimization
of cut-off values by iterative combination of biomarkers
and thresholds (rule-induction-like method) [18]. Highly
specific combinations of three molecules were com-
puted. Those showing the highest pAUC for discrimin-
ation between stage 1 and stage 2 patients were kept.
Statistical comparison between the pAUC of the panels
and those of the individual markers was obtained
through the Bootstrap test for two correlated ROC
curves.
Results
Concentration of markers in patients’ CSF
The CSF levels of IgM, B2MG, MMP-9, CXCL13,
CXCL10, ICAM-1, VCAM-1 and neopterin were mea-
sured on a population of 85 patients, comprising 14
stage 1 and 71 stage 2 (Table 1).
All molecules showed a higher CSF concentration in
S2 patients compared to S1. IgM, MMP-9 and CXCL13
showed the highest fold increase (S2/S1 concentration
ratio of 68, 12 and 187, respectively). However, the com-
parison using the Mann–Whitney U test, highlighted
significant differences between the two stages for all
markers (Table 2). These differences were confirmed
when patients from Uganda (S1 n=11; S2 n=44) were
considered separately, while only MMP-9, IgM and
B2MG could significantly discriminate between Mala-
wian S1 (n=3) and S2 (n=27) patients (Additional
Figure 1). Furthermore, all markers significantly correlated
(Spearman correlation) with the number of WBC counted
in the CSF, the current staging method, with MMP-9,
CXCL13 and CXCL10 having a rho coefficient > 0.5
(Table 2).Table 2 Concentration of markers in early (S1) and late (S2) s
Marker [S1], median [S2], median
IgM [μg/mL] 0.96 65.4
MMP-9 [pg/mL] 108.6 1309.9
CXCL13 [pg/mL] 8.2 1531.2
VCAM-1 [ng/mL] 22.6 67.3
B2MG [ng/mL] 964 3447
ICAM-1 [ng/mL] 1.99 9.6
Neopterin [nmol/L] 41.2 112.9
CXCL10 [ng/mL] 8.9 41.9
* Mann–Whitney U test.
† Correlation between the number of CSF WBC and CSF levels for each marker. CorStaging ability of the markers
ROC analyses were performed to further assess the abil-
ity of the markers to discriminate between S1 and S2
patients in terms of specificity and sensitivity.
To highlight markers able to correctly rule out the
highest number of S1 patients, partial AUC between 90
and 100% of specificity were calculated together with a
cut-off in marker concentration at 100% of SP (Figure 1,
Additional file 1: Table 2).
IgM, MMP-9 and CXCL13 had a pAUC higher than
80%, but for 100% of specificity IgM showed higher sen-
sitivity (SE 77%, 76.6-87.3 95% CI), compared to MMP-9
(72% SE, 60.6-81-7 95% CI) and CXCL13 (69% SE,
57.8-80.3 95% CI).
A second group of markers with a pAUC between 70-
80% comprised VCAM-1, B2MG, ICAM-1 and neop-
terin. CXCL10 was highlighted as the less accurate mar-
ker, with a pAUC of only 55% and 3% sensitivity for
100% specificity.
To further assess the ability of the eight molecules to
identify patients with advanced S2 HAT, patients were
classified based on the absence (T-, n=21) or the pres-
ence (T+, n=64) of parasites in the CSF. The total area
under the ROC curve was considered. All markers, ex-
cept neopterin and CXCL10, discriminated between
T- and T+ patients with AUC > 80% and with perfor-
mances comparable to those of WBC (95% CI around
AUC overlapping) (Table 3).
Interestingly, when the specificity and sensitivity corre-
sponding to the best cut-off were taken into account, the
three best markers, i.e. IgM, MMP-9 and CXCL13,
turned out to be more specific (SP > 85%) than WBC,
which in turn was more sensitive (SE > 95%) (Table 3).
Combination of markers into panels
To evaluate whether a combination of markers could in-
crease the staging ability, panels of three molecules cor-
responding to 100% specificity were calculated. Two
different combinations showing the same staging perfor-
mances (pAUC 94%, 89.9-97.3 95% CI; SE 87.3%, 78.9-tage T.b. rhodesiense patients
[S2]/[S1] p value* Spearman rho†
68.1 <0.0001 0.491
12.1 <0.0001 0.554
186.7 <0.0001 0.529
3.0 <0.0001 0.372
3.6 <0.0001 0.426
4.8 <0.0001 0.457
2.7 0.001 0.360
4.7 0.005 0.508
relation was significant at 0.01 level.
Figure 1 ROC curves representing the staging abilities of the eight markers. Dark gray areas represent the corrected pAUC between 90 and
100% of specificity obtained for each marker. Light gray zones represent a pAUC of 100%. The value of the cut-off corresponding to 100%
specificity comprised within the pAUC is reported on each graph together with the corresponding sensitivity% (SE%). Additional results are
reported in Additional file 1: Table 2.
Table 3 Ability of markers to classify T.b. rhodesiense patients according to the presence of parasites in CSF
Marker p value* AUC% (95% CI) Cut-off SP% (95% CI) SE% (95% CI)
IgM [μg/mL] < 0.0001 84.5 (73.9-95.2) 17.8 85.7 (66.7-100) 81.3 (71.9-90.6)
MMP-9 [pg/mL] < 0.0001 85.2 (74.3-96) 499.8 90.5 (76.2-100) 76.6 (65.6-85.9)
CXCL13 [pg/mL] < 0.0001 80.4 (69.1-91.8) 200.3 90.5 (76.2-100) 73.4 (62.5-84.4)
VCAM-1 [ng/mL] < 0.0001 83.2 (73.7-92.7) 43.9 76.2 (57.1-90.5) 78.1 (67.2-87.5)
B2MG [ng/mL] < 0.0001 82.0 (71.3-92.7) 1462 66.7 (47.6-85.7) 85.9 (76.6-93.8)
ICAM-1 [ng/mL] < 0.0001 83.3 (73–93.6) 4.7 81.0 (61.9-95.2) 73.4 (62.5-84.4)
Neopterin [nmol/L] < 0.0001 75.5 (63.9-87.1) 69.4 81.0 (61.9-95.2) 65.6 (54.7-76.6)
CXCL10 [ng/mL] 0.002 73.1 (59.3-86.8) 7.5 47.6 (28.6-66.7) 92.2 (84.4-98.4)
WBC (Cells/μL) < 0.0001 87.4 (77.4-97.4) 6.5 71.4 (52.4-90.5) 95.3 (89.1-100)
Patients without parasites detected in CSF, n=21; patients with parasite detected in CSF, n=64.
* Mann–Whitney U test.
SP% = specificity%; SE% = sensitivity%; 95% CI = 95% confidence interval.
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CXCL10 (cut-off 2.24 ng/mL) and CXCL13 (cut-off 23.3
pg/mL) in combination with either MMP-9 (cut-off
499.8 pg/mL) or IgM (cut-off 17.8 μg/mL) (Table 4).
Both panels were considered positive when at least two
out of three molecules were above their cut-offs.
When compared to the individual molecules, the two
panels were significantly more accurate for stage deter-
mination (Bootstrap test for two correlated ROC curves,
p<0.05). These combinations enabled the correct classifi-
cation of all S1 patients (100% SP) and 62 out of 71 S2
patients (87% SE).
Discussion
Stage determination in T. b. rhodesiense sleeping sick-
ness patients is a critical step in ensuring that the appro-
priate treatment is used [14]. An imperfect gold
standard for staging and the lack of a safe S2 drug high-
light the need for new tools for staging this form of dis-
ease [27,28]. In the present study we investigated, on a
small population of patients suffering from T. b. rhode-
siense HAT, a number of molecules (MMP-9, CXCL10,
CXCL13, IgM, neopterin, ICAM-1, VCAM-1 and
B2MG) known to be over-expressed in the CSF of late
stage T. b. gambiense patients [23]. Since melarsoprol is
still the only treatment for S2 rhodesiense patients, we
evaluated their staging ability as highly specific markers,
to try to limit unnecessary exposure of patients to this
toxic drug. IgM, MMP-9 and CXCL13 were shown to be
the most accurate discriminators between early and late
stage disease (pAUC ≥ 85%) and showed the same accur-
acy as WBC in distinguishing between patients having
parasites in their CSF from those without. Furthermore,
combination of the molecules into panels of three mar-
kers (IgM-CXCL13-CXCL10 or MMP-9-CXCL13-
CXCL10) significantly increased the staging accuracy,
leading to the correct classification of all S1 patients and
62 out of 71 S2 patients.
All the markers investigated here are known to be
involved in the immune response elicited by the pres-
ence of the parasite in the host. Interestingly, a differentTable 4 Panels of markers for staging T.b. rhodesiense patien
Panel Markers Cut-off p
1 CXCL10 [ng/mL] 2.2
CXCL13 [pg/mL] 23.3
MMP-9 [pg/mL] 499.8
2 CXCL10 [ng/mL] 2.2
CXCL13 [pg/mL] 23.3
IgM [μg/mL] 17.8
* pAUC and SE% were calculated for 100% SP.
† Comparison between the pAUC (90-100% SP) of the panel and those of the mark
correlated ROC curves.
Both panels are positive when ≥2 molecules are above their cut-off.behavior of the 8 molecules was observed in T. b. gam-
biense patients, which may reflect the differences in
immunopathogenesis [29] and clinical presentation
[3,30] of the two forms of HAT. It has already been pro-
posed, for example, that different activation pathways of
macrophages and astrocytes may take place in the two
forms of HAT [22]. Such differences may be responsible
of the less accurate staging ability of neopterin on T. b.
rhodesiense patients, compared to its very high staging
power on T. b. gambiense patients.
The role of IgM, the best individual marker in the
present study, in disease progression has been exten-
sively studied. An increased CSF concentration of IgM
of intrathecal origin was shown to be a good indicator of
brain involvement in HAT [15], leading to the develop-
ment of a rapid latex agglutination test (Latex/IgM) for
stage determination in the field [31]. However, when
assessed under field conditions, this assay did not repre-
sent an advantage compared to counting of WBC [31].
Furthermore, when used for evaluation of the outcome
after treatment, IgM levels were not an optimal indicator
of recovery due to their slow normalization [32]. Studies
in animal models have shown that HAT meningo-
encephalitis is characterized by an increased number of
leukocytes in the CNS [33]. CXCL13, also known as
BCA-1, is a chemokine mainly produced by dendritic
cells [34], which specifically attracts B and T lympho-
cytes to the site of inflammation [35]. Its over-
expression in CSF has been associated with increased
WBC and intrathecal production of immunoglobulins in
many pathological conditions [36,37], including late
stage T. b. gambiense HAT [19]. On the other hand,
MMP-9 (matrix-metalloproteinase 9), an enzyme invol-
ved in tissue homeostasis and remodeling [38,39], has
been extensively studied in a number of pathologies af-
fecting the CNS [39-42], in addition to T. b. gambiense
HAT [17]. Due to its ability to degrade β-dystroglycan,
this protein has been proposed to be involved in the pas-
sage of leukocytes through the glia limitans to reach the
brain parenchyma [43]. However, the temporal relationship
between the events leading to CNS invasion and thets obtained through a combination of 3 molecules
AUC% (95% CI)* SE% (95%CI)* p value†
94 (89.9-97.3) 87.3 (78.9-94.4) 0.0001
0.01
0.01
94 (89.9-97.3) 87.3 (78.9-94.4) 0.0001
0.01
0.02
ers individually considered obtained through the Bootstrap test for two
Tiberti et al. Clinical and Translational Medicine 2013, 2:1 Page 6 of 8
http://www.clintransmed.com/content/2/1/1appearance of various signs and symptoms of nervous sys-
tem dysfunction needs to be investigated further.
The markers investigated in the present study were
combined into panels in order to increase their accuracy
in stage determination. The utility of this approach to
achieve a better diagnostic accuracy has already been
shown [18,44]. Using this method, we highlighted highly
specific combinations comprising CXCL13, CXCL10 and
MMP-9 or IgM. Interestingly, CXCL10 was present in
both panels. This molecule was not efficient in staging
T. b. rhodesiense patients when considered individually.
However, when combined to CXCL13 and MMP-9 or
IgM, it helped in reaching a significantly increased staging
accuracy. This chemokine, which specifically attracts T
lymphocytes to the site of inflammation [45], was reported
to be produced by activated astrocytes in trypanosome-
infected mice [46]. The activation of astrocytes and ma-
crophages are early events in stage 2 infection [47-49],
suggesting that CXCL10 may represent an early indicator
of CNS involvement in HAT.
Interestingly, the markers did not show the same sta-
ging performances when assessed on patients classified
according to their geographic origin (i.e. Malawi or
Uganda). Although the low number of Malawian S1
patients (n=3) certainly represents a bias and may be re-
sponsible for the differences observed, this result could
reflect the variable clinical presentation of rhodesiense
disease observed in different foci [27]. This may suggest
that potentially different markers will be needed to stage
T. b. rhodesiense patients according to their geographical
origin and the parasite strain.
The present study has a number of limitations that
should be considered. First, the data presented resulted
from analyses on a small number of patients. This is a
common problem associated to the investigation of this
form of HAT. Collecting samples from T. b. rhodesiense
patients is considerably difficult, not only due to the
lower incidence of this disease compared to the gam-
biense form, but also as a consequence of a less effective
active screening, since the CATT test can only detect T.
b. gambiense cases [50]. To further evaluate the staging
properties of the markers, larger cohorts of patients
should be investigated. Moreover, due to the reported
differences between T. b. rhodesiense HAT among foci,
the results presented here should be validated in a more
controlled set of patients (i.e. in which the same para-
sitological examinations were performed).
Another drawback could be represented by the choice
of selecting highly specific markers, with the conse-
quence of compromising the sensitivity. Management of
T. b. rhodesiense patients is far from being optimal, thus
both choices of high specificity or sensitivity would be
associated either to a risk of missing the diagnosis of late
stage patients, or to the exposure of S1 patients to ahighly toxic stage 2 drug, respectively. However, it
should be emphasized that a new staging biomarker for
rhodesiense HAT would be combined with the detection
of parasites in CSF, which would increase the sensitivity,
and with clinical evaluation of the neurological status of
the patients.
The absence of information on neurological signs exhib-
ited by patients in the present study prevented an efficient
assessment of the association between the levels of the
markers and the signs of CNS involvement. This aspect is
particularly important in the light of a recent publication
on T. b. rhodesiense HAT reporting the poor association
between disease progression, the levels of a number of
cytokines and patients’ neurological manifestations [51].
The 8 markers investigated here behaved differently
when assessed on T. b. gambiense or T. b. rhodesiense
samples, underlining the differences between the two
forms of disease, and suggesting that potentially new
rhodesiense-specific markers could be discovered.
Despite the high staging accuracy shown by the com-
binations of markers described in the present study (i.e.
CXCL10-CXCL13-MMP-9 and CXCL10-CXCL13-IgM),
their translation into a rapid field diagnostic test could
be difficult, due to a potential increase in the costs of
production, suggesting that deeper investigations should
be performed. The individual staging power of the mole-
cules should be assessed on a larger cohort of T. b. rho-
desiense HAT patients, including CSF samples collected
during the post-therapeutic follow-up, and the possibility
of their translation into a point-of-care test for stage de-
termination in the field should be evaluated. Further-
more, their study in animal models, as already done for
IL-10 [52], could help in the further characterization of
the role of these markers in disease progression.
Conclusions
The results presented in this work on T. b. rhodesiense
sleeping sickness highlight the potential utility of IgM,
MMP-9 and CXCL13, alone or combined with CXCL10
in staging patients. We believe that this work has paved
the way for further investigations on the role of these
markers in detecting the meningo-encephalitic stage of
T. b. rhodesiense HAT, and therefore making a more ac-
curate choice of treatment.Additional file
Additional file 1: Table 1. Details of the studies from which samples
were obtained. Table 2. Detailed calculation for the evaluation of the
staging ability of the eight markers. Figure 1. Comparison of the levels of
the markers between stage 1 (S1) and stage 2 (S2) T.b. rhodesiense
patients classified according to the country of sample collection. For each
country, differences between S1 and S2 were assessed using the Mann-
Whiney U test. * corresponds to a p value < 0.05; ** corresponds to a p
value < 0.001; *** corresponds to a p value < 0.0001.
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